Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL4934731 | 0.98 | ALDH1A1 (0.59) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL8226148 | 0.88 | TTR (0.47) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL2302437 | 0.86 | MAPT (0.51) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL3085306 | 0.85 | MAPT (0.51) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL5022275 | 0.84 | NPC1 (0.52) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL531792 | 0.84 | MAPT (0.50) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL30542902 | 0.84 | MAPT (0.50) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL937021 | 0.83 | MAPT (0.66) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| SCHEMBL3922628 | 0.83 | ALDH1A1 (0.49) | ALDH1A1HPGDL3MBTL1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL31032930 | 0.83 | MAPT (0.49) | ALDH1A1HPGDL3MBTL1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105712952-B | 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-1867554-B | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2008-11-20 | — | — | US | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-0858453-A1 | 5-(ACETAMIDOMETHYL)-3-ARYLDIHYDROFURAN-2-ONE AND TETRAHYDROFURAN-2-ONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | AstraZeneca AB (SE) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997014690-A1 | 5-(ACETAMIDOMETHYL)-3-ARYLDIHYDROFURAN-2-ONE AND TETRAHYDROFURAN-2-ONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ZENECA LIMITED (GB) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | ALDH1A1 1436/4885HPGD 885/4885L3MBTL1 2359/4885 |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | SULT1A1, SULT2A1, SULT1E1 | ALDH1A1 871/4885HPGD 1587/4885L3MBTL1 968/4885 |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | ALDH1A1 395/4885HPGD 1222/4885L3MBTL1 3524/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | ALDH1A1 582/4885HPGD 1651/4885L3MBTL1 1777/4885 |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | OPRL1, ACHE, PNMT | ALDH1A1 582/4885HPGD 1651/4885L3MBTL1 1777/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ALDH1A1 591/4885HPGD 2371/4885L3MBTL1 3697/4885 |
| US-20080287455-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES | SULT1A1, SULT2A1, SULT1E1 | ALDH1A1 871/4885HPGD 1587/4885L3MBTL1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.